Topic

Cometriq (cabozantinib)

A collection of 35 issues

How to Get Cometriq (Cabozantinib) Covered by Aetna CVS Health in Illinois: Prior Authorization Guide and Appeals Process

Answer Box: Getting Cometriq Covered by Aetna CVS Health in Illinois Cometriq (cabozantinib) requires prior authorization from Aetna CVS Health for medullary thyroid carcinoma (MTC) coverage. Submit your PA request via the Availity provider portal or fax to 1-888-267-3277 with oncologist attestation, confirmed MTC diagnosis, and documentation of disease progression.

How to Get Cometriq (cabozantinib) Covered by UnitedHealthcare in Michigan: Complete PA Guide with Forms and Appeals

Getting Cometriq (cabozantinib) covered by UnitedHealthcare in Michigan requires prior authorization for metastatic medullary thyroid carcinoma (MTC) or progressive thyroid cancers after failed step therapy. Submit via the UHC Provider Portal with diagnosis confirmation, or call 866-889-8054. If denied, you have 180 days for internal appeals and 127 days for

How to Get Cometriq (Cabozantinib) Covered by UnitedHealthcare in North Carolina: Complete Prior Authorization & Appeals Guide

Answer Box: Getting Cometriq Covered by UnitedHealthcare in North Carolina UnitedHealthcare requires prior authorization for Cometriq (cabozantinib capsules) in North Carolina, primarily for progressive, metastatic medullary thyroid cancer (MTC). Submit PA through your oncologist via the UHC Provider Portal with pathology reports, imaging showing progression, and ICD-10 codes. If denied,

How to Get Cometriq (Cabozantinib) Covered by Cigna in Pennsylvania: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Cometriq Covered by Cigna in Pennsylvania Cigna covers Cometriq (cabozantinib capsules) for metastatic medullary thyroid carcinoma with prior authorization. Your oncologist submits a PA request including pathology confirming MTC diagnosis, recent imaging showing progression, and elevated calcitonin/CEA levels. If denied, Pennsylvania's new Independent External

How to Get Cometriq (cabozantinib) Covered by Blue Cross Blue Shield in New Jersey: Complete Prior Authorization and Appeals Guide

Quick Answer: Getting Cometriq Covered in New Jersey Cometriq (cabozantinib capsules) requires prior authorization from Blue Cross Blue Shield in New Jersey for metastatic medullary thyroid carcinoma. Your oncologist submits the PA electronically with pathology reports, imaging showing progression, and medical necessity documentation. If denied, you have 180 days to

How to Get Cometriq (Cabozantinib) Covered by Cigna in Ohio: Coding, Prior Authorization, and Appeals Guide

Answer Box: Getting Cometriq Covered by Cigna in Ohio Cometriq (cabozantinib capsules) requires prior authorization from Cigna for metastatic medullary thyroid carcinoma. Key steps: 1) Submit PA with ICD-10 code C73, progression documentation, and Cometriq-specific prescription (not Cabometyx tablets), 2) If denied, file internal appeal within 180 days, 3) Request

Getting Cometriq (Cabozantinib) Covered by Humana in Michigan: Complete Prior Authorization and Appeals Guide

Answer Box: Fast Track to Cometriq Coverage To get Cometriq (cabozantinib) covered by Humana in Michigan: Your doctor must submit a prior authorization request through Humana's provider portal or by calling 800-555-2546, including diagnosis of metastatic medullary thyroid carcinoma, elevated calcitonin levels, and documentation that Cometriq capsules (not

How to Get Cometriq (Cabozantinib) Covered by Blue Cross Blue Shield in Ohio: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Cometriq Covered in Ohio Blue Cross Blue Shield of Ohio (Anthem BCBS OH) requires prior authorization for Cometriq (cabozantinib capsules) for progressive/metastatic medullary thyroid carcinoma. First step: Verify your diagnosis meets criteria (confirmed MTC with progression, no active bleeding/GI issues). Fastest path: Submit PA via

How to Get Cometriq (cabozantinib) Covered by Cigna in Michigan: Complete PA and Appeals Guide

Answer Box: Getting Cometriq (cabozantinib) Covered by Cigna in Michigan Cometriq requires prior authorization through Cigna and must be dispensed through Accredo specialty pharmacy. Your oncologist submits clinical documentation proving medullary thyroid carcinoma (MTC) diagnosis with standard review completed within 72 hours. If denied, you have 180 days for internal

Renewing Cometriq (Cabozantinib) Approval with Blue Cross Blue Shield in Washington: Complete Timeline and Documentation Guide

Quick Answer: Blue Cross Blue Shield Washington typically requires renewal every 6-12 months for Cometriq (cabozantinib) with documented stable disease or response via imaging (CT/MRI every 2-3 months) and biochemical markers (calcitonin/CEA). Submit renewal 2-4 weeks before expiration through your oncologist with recent scans, lab trends, and toxicity